Probiotics: a promising future in the treatment of ulcerative colitis?
- PMID: 40214948
- DOI: 10.1007/s43440-025-00724-7
Probiotics: a promising future in the treatment of ulcerative colitis?
Abstract
Ulcerative colitis is an idiopathic and chronic inflammatory bowel disease, characterized by inflammation of the mucosa of the colon and rectum. Clinical manifestations commonly include abdominal pain, diarrhea (with or without hematochezia), and weight loss. The pathogenesis of ulcerative colitis is multifactorial, involving a combination of genetic predispositions and lifestyle factors. High consumption of processed food, sedentary habits, alcohol intake, and stress are among the lifestyle factors implicated in disease onset and progression. Current treatment strategies focus on managing symptoms and inducing remission, however, the chronic nature of the disease, along with the adverse effects of conventional therapies, often compromises patient's quality of life. Therefore, exploring alternative therapies that can prolong remission and reduce symptom burden is important. Experimental evidence suggests that probiotics may extend remission duration in ulcerative colitis. Moreover, probiotics exhibit efficacy in amelioration clinical symptoms by reducing inflammation markers, preserving, and restoring intestinal epithelial. This review explores the advantages of the administration of probiotics in the treatment of ulcerative colitis, elucidating their mechanism of action.
Keywords: Gut health; Gut microbiome; Inflammation; Inflammatory bowel disease; Oxidative stress.
© 2025. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences.
Conflict of interest statement
Declarations. Ethics and consent to participate declarations: Not applicable, as this study is a review article and does not involve the collection of data from human or animal subjects. Competing interests: The authors declare no competing interests.
Similar articles
-
Use of Synbiotics for Ulcerative Colitis Treatment.Curr Clin Pharmacol. 2020;15(3):174-182. doi: 10.2174/1574884715666191226120322. Curr Clin Pharmacol. 2020. PMID: 31878863 Review.
-
Evaluating the Therapeutic Efficacy of Lactobacillus Strains in the Management of Ulcerative Colitis: An Overview of Recent Advances.Curr Pharm Des. 2025;31(6):413-421. doi: 10.2174/0113816128322653240925115114. Curr Pharm Des. 2025. PMID: 39385420 Review.
-
Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?Curr Clin Pharmacol. 2020;15(3):216-233. doi: 10.2174/1574884715666200312100237. Curr Clin Pharmacol. 2020. PMID: 32164516 Review.
-
Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation.World J Gastroenterol. 2018 Jan 7;24(1):5-14. doi: 10.3748/wjg.v24.i1.5. World J Gastroenterol. 2018. PMID: 29358877 Free PMC article. Review.
-
Probiotics (Lactobacillus plantarum HNU082) Supplementation Relieves Ulcerative Colitis by Affecting Intestinal Barrier Functions, Immunity-Related Gene Expression, Gut Microbiota, and Metabolic Pathways in Mice.Microbiol Spectr. 2022 Dec 21;10(6):e0165122. doi: 10.1128/spectrum.01651-22. Epub 2022 Nov 2. Microbiol Spectr. 2022. PMID: 36321893 Free PMC article.
Cited by
-
Evaluation of Lacticaseibacillus casei 39 Paraprobiotic in Modulating Inflammatory and Oxidative Pathways in Acetic Acid Induced Ulcerative Colitis.Food Sci Nutr. 2025 Jul 18;13(7):e70476. doi: 10.1002/fsn3.70476. eCollection 2025 Jul. Food Sci Nutr. 2025. PMID: 40688608 Free PMC article.
References
-
- Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;29(10080):1756–70. https://doi.org/10.1016/S0140-6736(16)32126-2 . - DOI
-
- Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, et al. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65(12):100851. https://doi.org/10.1016/j.disamonth.2019.02.004 . - DOI - PubMed
-
- Aslam N, Lo SW, Sikafi R, Barnes T, Segal J, Smith PJ, et al. A review of the therapeutic management of ulcerative colitis. Th Adv Gastroenterol. 2022;29:15:17562848221138160. https://doi.org/10.1177/17562848221138160 . - DOI
-
- Latif A, Shehzad A, Niazi S, Zahid A, Ashraf W, Iqbal MW, et al. Probiotics: mechanism of action, health benefits and their application in food industries. Front Microbiol. 2023;17:14:1216674. https://doi.org/10.3389/fmicb.2023.1216674 . - DOI
-
- Palumbo VD, Romeo M, Marino Gammazza A, Carini F, Damiani P, Damiano G, et al. The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160(3):372–7. https://doi.org/10.5507/bp.2016.044 . - DOI - PubMed
Publication types
MeSH terms
Grants and funding
- 305740/2019-9/Conselho Nacional de Desenvolvimento Científico e Tecnológico
- 309431/2022-0/Conselho Nacional de Desenvolvimento Científico e Tecnológico
- 308220/2021-8/Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Edital 15/2022 - PROFIX: 708/2022/Fundação de Amparo à Pesquisa e Inovação do Espírito Santo
- Edital 15/2022 - PROFIX: 630/2022/Fundação de Amparo à Pesquisa e Inovação do Espírito Santo
LinkOut - more resources
Medical